Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension

Treprostinil is a potent prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH, World Health Organization Group I). Previously, treprostinil was available only in subcutaneous (SC) or intravenous (IV) formulations. Availability of an inhaled formulation of trep...

Descripción completa

Detalles Bibliográficos
Autores principales: Raina, Amresh, Coons, James C., Kanwar, Manreet, Murali, Srinivas, Sokos, George, Benza, Raymond L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641714/
https://www.ncbi.nlm.nih.gov/pubmed/23662183
http://dx.doi.org/10.4103/2045-8932.109926

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641714/
https://www.ncbi.nlm.nih.gov/pubmed/23662183
http://dx.doi.org/10.4103/2045-8932.109926

Ejemplares similares